RE:Zenith Update Perspectives Nice summary Toniv. I think your 93 billion as meant to be 9.3 billion.
I was a little disappointed that DM DID NOT address some of our previous inquries such as how compounds/disease indications are split between RVX/Zenith (RVX has ~1000 compounds, Zenith ~1500 compounds), status of autoimmune program (MIA from their website), or status of other pre-clinical molecules such as RVX297 (recently published). Nothing new on the licensing deal (though he made comment of having one by end of 2016) or animal health indication opportunities (mentioned in January webcast) either.
As you indicated, we did learn that the closing date for the re-organization will be July 31, 2016. So at that point our royalty-holding Zenith Capital Corp shares should be protected from further dilution and will be separate from the Zenith Epigenetics Ltd and whatever may become of it.
As for the prostate cancer trial, they should finish enrolling their first cohort by next week and will have PK/Safety data in Fall 2016. There was a very good slide on how the dose escalation portion of the slide works in determining the maximum tolerated dose. It's a 3+3 design, so first cohort is 3 patients at first dose for 28 days. If no dose limited toxicities (DLT), they add in 3 patients at the next highest dose and see what happens at that dose for 28 days. Rinse and repeat until the maximally tolerated dose is found, defined as no more than 1 patient out of 6 with a DLT at a given dose. All sites but UCLA are activated, and UCLA is anticipated to be activated very soon. They will expand to combination therapies in H2 2016. They expect to reach proof of concept H1 2017, which seems much later than the initial estimates (or maybe we had a misconception about this?). But if all goes well with initial trial they are still looking to expand into other solid tumours such as breast cancer, head&neck cancer and hematological malignancies in 2017. So sounds like trial planning and execution is going very well.
Only 1 person during the Q&A and it was George Zavoico. He asked something to the effect of what differentiates Zenith's pan inhibitor from the others in clincial trials. Don answered that what differentiates Zenith's pan-inhibitor is that it is more selective to BRD4 than the other bromodomain proteins.
BearDownAZ